Preclinical data consistently show neuroprotective effects, though the dedicated EVOKE trial of semaglutide for Alzheimer's disease found no significant benefit
Semaglutides starting dose begins at a modest .25mg, usually administered as a weekly injection, and gradually escalates to a target dose of 2.4mg after roughly 16 weeks
Freitas S, Merkle HP, Gander B
Market Segmentation Global Glucagon-Like Peptide-1 Agonists Market Size, Share & Industry Analysis, By Product Type (Short-Acting GLP-1 Agonists, Long-Acting GLP-1 Agonists), By Route of Administration (Injectable, Oral), By Application (Type 2 Diabetes, Obesity Management, Cardiovascular Disease Management), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Analysis and Forecast 20262035 Global Glucagon-Like Peptide-1 Agonists Market Size & Statistics The Market size of global glucagon-like peptide-1 agonists was estimated to be worth USD 46.18 Billion in 2025
Moreover, individuals with diabetes require continuous monitoring to prevent acute complications such as hypoglycemia and diabetic ketoacidosis
The shift in gut motility, combined with changes in bile acid absorption and fluid balance in the intestines, can lead to diarrhea, particularly during dose increases
